Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
Key Highlights
- ➤Approximately $90 million raised through equity and debt financing since October 2023
- ➤FDA authorized initiation of SKNJCT-005 registrational study for Gorlin syndrome patients
- ➤SkinJect 200-microgram dose selected for further development after Phase 2 study
- ➤Medicus submitted optimized registrational protocol for Teverelix advanced prostate cancer
- ➤CD228V development initially targets relapsed, refractory, or immunotherapy-resistant melanoma
Expert Statements
Carolyn Bonner, President and Chief Financial Officer of Medicus Pharma Ltd.
“Our strategy is to identify promising therapeutic assets with existing scientific and clinical foundations and concentrate incremental investment on milestones that can strengthen their development prospects and partnering value.”
Carolyn Bonner, President and Chief Financial Officer of Medicus Pharma Ltd.
“We must make a concerted effort to explain more clearly, when we can, how the investments made to date position Medicus and support that explanation with measurable results.”
PHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today provided a shareholder update celebrating its third anniversary, highlighting three years of progress, focused on execution and capital efficient drug development. The Company has advanced its transformation into a precision oncology-led biotechnology company, with a portfolio of select novel assets, anchored by CD228V, an investigational antibody-drug conjugate molecule utilizing Pfizer’s established vedotin linker-payload platform, SkinJect for basal cell carcinomas in patients with Gorlin syndrome and Teverelix for development opportunities in urology and women’s health.
This transformation, outlined in our recent strategic update, reflects progress in clinical advancement, strategic acquisitions, and investment in the people and capabilities needed to execute. From a company centered on SkinJect, we have built a portfolio with multiple potential paths to clinical and commercial value.
Get started
Create a free account to read the full story.